— Amgen shares fell 3.7% after the approval of Bristol-Myer Squibb's psoriasis drug, which will compete with Amgen's Otezla.
Separately, the biotech company reported over the weekend that its Lumakras pill reduced the risk of lung cancer progression by 34% compared with chemotherapy in a clinical trial,
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Malaysia Malaysia Latest News, Malaysia Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks Making the Biggest Moves Premarket: Carvana, Bristol-Myers Squibb, Alphatec and MoreThese are the stocks posting the largest moves in premarket trading.
Source: nbcsandiego - 🏆 524. / 51 Read more »
Twitter whistleblower testimony, consumer price index, Oracle earnings top week aheadFOX Business takes a look at the upcoming events that are likely to move financial markets in the coming days, including some big matters for Twitter. “Every statue and street building has been renamed, every date has been altered. And the process is continuing day by day and minute by minute. History has stopped. Nothing exists except an endless present in which the Party is always right.” - George Orwell, 1984
Source: FoxBusiness - 🏆 458. / 53 Read more »